V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Travere Therapeutics Executive Compensation (FY25)

TVTX · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): May 21, 2026
350 figures on this page: 339 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Eric Dube
Latest say-on-pay support
=
May 19, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Eric Dube: $5,204,877 → $8,457,151 (62.5% higher)
Say-on-pay support: 96.3% → 97.2% (0.9 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Travere Therapeutics' chief executive and what were they paid?
Eric Dube was paid $8,457,151 in total compensation as President, Chief Executive Officer and Director for fiscal 2025. Compared with the $5,204,877 reported for fiscal 2024, Dube's total was 62.5% higher.
What was Travere Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 97.2% of votes cast including abstentions in favor at the meeting held May 19, 2026.
Which companies are in Travere Therapeutics' peer group?
The disclosed peer group names Coherus BioSciences, Collegium Pharmaceutical, Corcept Therapeutics, Dynavax Technologies and Harmony Biosciences, among others.
What is Travere Therapeutics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 23:1, against median employee compensation of $364,999.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Dube
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
William Rote
Chief Research Officer
◇—◇◇◇—◇◇
Peter Heerma
Chief Commercial Officer
◇—◇◇◇—◇◇
Jula Inrig
Chief Medical Officer
◇—◇◇◇—◇◇
Christopher Cline
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Dube
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Jula Inrig
Chief Medical Officer
◇—◇◇◇—◇◇
William Rote
Chief Research Officer
◇—◇◇◇—◇◇
Peter Heerma
Chief Commercial Officer
◇—◇◇◇—◇◇
Christopher Cline
Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Eric Dube
President, Chief Executive Officer and Director
◇—◇◇◇—◇◇
Jula Inrig
Chief Medical Officer
◇—◇◇◇—◇◇
Peter Heerma
Chief Commercial Officer
◇—◇◇◇—◇◇
William Rote
Chief Research Officer
◇—◇◇◇—◇◇
Christopher Cline
Chief Financial Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher ClinePSU◇—◇—◇—◇
Christopher ClineRSU◇——◇——◇
Christopher ClineOPTION◇——◇—◇◇
Eric DubeOPTION◇——◇—◇◇
Eric DubePSU◇—◇—◇—◇
Eric DubeRSU◇——◇——◇
Jula InrigRSU◇——◇——◇
Jula InrigPSU◇—◇—◇—◇
Jula InrigOPTION◇——◇—◇◇
Peter HeermaOPTION◇——◇—◇◇
Peter HeermaRSU◇——◇——◇
Peter HeermaPSU◇—◇—◇—◇
William E. RoteRSU◇——◇——◇
William E. RoteOPTION◇——◇—◇◇
William E. RotePSU◇—◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Jula InrigOption◇—◇1/31/2035
Option◇—◇1/1/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2033
Christopher ClineRSU◇◇——
RSU◇◇——
Option◇—◇4/10/2032
RSU◇◇——
Option◇—◇1/31/2033
Option◇—◇9/1/2032
Option◇—◇1/31/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2035
RSU◇◇——
Option◇—◇1/31/2032
RSU◇◇——
Peter HeermaOption◇—◇1/31/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2034
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2033
RSU◇◇——
Option◇—◇1/31/2035
RSU◇◇——
William RoteOption◇—◇1/31/2035
Option◇—◇1/31/2034
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2033
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2032
RSU◇◇——
Eric DubeOption◇—◇1/31/2034
Option◇—◇1/31/2032
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2035
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2033
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Gary Lyons
◇◇◇———◇
Jeffrey Meckler
◇◇◇———◇
Roy Baynes
◇◇◇———◇
John A. Orwin
◇◇◇———◇
Suzanne Bruhn
◇◇◇———◇
Sandra Poole
◇◇◇———◇
Ron Squarer
◇◇◇———◇
Ruth Williams-Brinkley
◇◇◇———◇
Eric Dube and Timothy Coughlin served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Coherus BioSciences CHRS
  • Collegium Pharmaceutical COLL
  • Corcept Therapeutics CORT
  • Dynavax Technologies DVAX
  • Harmony Biosciences HRMY
  • Ironwood Pharmaceuticals IRWD
  • Ligand Pharmaceuticals LGND
  • Mirum Pharmaceuticals MIRM
  • Pacira BioSciences PCRX
  • Phathom Pharmaceuticals PHAT
  • PTC Therapeutics PTCT
  • Rhythm Pharmaceuticals RYTM
  • Supernus Pharmaceuticals SUPN
  • Ultragenyx Pharmaceutical RARE
  • Vericel VCEL
  • Xeris Biopharma XERS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2024May 15, 2025=◇◇◇
2023May 8, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 11, 2022=◇◇◇
2020May 14, 2021=◇◇◇
2019May 15, 2020=◇◇◇
2018May 8, 2019=◇◇◇
2017May 9, 2018=◇◇◇
2016May 17, 2017=◇◇◇
2015May 18, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Travere Therapeutics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Travere Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Travere Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Travere Therapeutics' disclosed peer group is defensible, who names Travere Therapeutics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
350 figures on this page: 339 cited to the filing that reported them, 11 calculated from figures it prints.
339 cited to the filing
11 calculated from the filing

Documents cited

  1. 0001438533-26-000046
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001438533-26-000027
    CEO Pay Ratio · DIRECTOR COMPENSATION SUMMARY · EXECUTIVE COMPENSATION · Grants of Plan-Based Awards · and 3 more sections
  3. 0001438533-25-000034
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001438533-25-000016
    Summary Compensation Table
  5. 0001438533-24-000022
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001438533-24-000012
    Summary Compensation Table
  7. 0001438533-23-000027
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001438533-22-000027
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001438533-21-000018
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001438533-20-000013
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001438533-19-000016
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-18-159397
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001438533-17-000019
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-16-596010
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Travere Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/TVTX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Travere Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Travere Therapeutics discloses

The companies named in TVTX's own disclosed peer group.

Coherus BioSciencesIronwood PharmaceuticalsMirum PharmaceuticalsPhathom PharmaceuticalsPTC TherapeuticsRhythm PharmaceuticalsSupernus PharmaceuticalsUltragenyx PharmaceuticalVericelXeris Biopharma

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy